Experience
Eli Lilly and Company
Zenith Goldline Pharmaceuticals
This ANDA case involved Zenith and two other generic drug manufacturers that attempted to invalidate Lilly's patent and thereby open the market for generic sales. The lengthy trial involved complex technical and legal issues. Lilly prevailed in the district court on all issues, protecting its exclusive marketing rights and a large revenue stream. The Federal Circuit later affirmed the lower court's decision, which upheld Lilly's patent on its blockbuster drug.
Eli Lilly and Company v. Zenith Goldline Pharmaceuticals, 1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
Eli Lilly and Company v. Zenith Goldline Pharmaceuticals, 05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa
The Hillman Group, Inc. v. KeyMe, LLC
The Hillman Group, Inc.
Bright Data Ltd. v. NetNut Ltd.
NetNut Ltd.
Hawk Technology Systems, LLC v. Castle Retail, LLC
Castle Retail, LLC
Japan Display Inc. f/k/a Hitachi Electronic Devices (USA), Inc. et al v. Tianma Microelectronics Co.
Tianma Microelectronics Co., Ltd.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Salient Systems Corporation v. Hawk Technology Systems LLC et al.
Salient Systems Corporation
Koninklijke Philips NV and IP2IPO Innovations, Ltd. v. Boston Scientific Corp.
Koninklijke Philips NV and IP2IPO Innovations, Ltd.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
Delta Faucet Company v. Globe Union Industrial Corp. et al.
Globe Union Industrial Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.